The impurity issues that started in Valsartan last summer led to Ranitidine and Nizatidine, and many drug products were discontinued. This year, the domestic pharmaceutical industry suffered greatly due to impurity risk all year round. Using a stigma called "carcinogen", a huge amount of medicines were recovered, and pharmaceutical companies suffered huge losses.

So far, the government's follow-up on impurity drugs has been a fear to pharmaceutical companies. From the Valsartan to Nizatidine, the pharmaceutical industry continued to report that the domestic measures were strong.

Valsartan immediately suspended the sale of products using the company's drug substance when recalls were recei